Related Experiment Video

Updated: Jul 6, 2026

Easy and Reproducible Low-Density Primary Culture using Frozen Stock of Embryonic Hippocampal Neurons
04:26

Easy and Reproducible Low-Density Primary Culture using Frozen Stock of Embryonic Hippocampal Neurons

Published on: January 27, 2023

Decreased drebrin mRNA expression in Alzheimer disease: correlation with tau pathology

Carl Julien1, Cyntia Tremblay, Farid Bendjelloul

  • 1Molecular Endocrinology and Oncology Research Center, Centre Hospitalier de l'Universitè, Laval Research Center, Quebec, Quebec, Canada.

Journal of Neuroscience Research
|March 15, 2008
PubMed

Insights

Alzheimer's disease (AD) is linked to reduced drebrin mRNA in key brain regions. This decrease correlates with disease progression and tau pathology, suggesting drebrin's role in AD.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pathology

Background:

  • Alzheimer's disease (AD) is a neurodegenerative disorder characterized by protein aggregates and cognitive decline.
  • Dendritic spines are crucial for synaptic plasticity and are affected in AD.
  • Drebrin is a dendritic spine protein implicated in synaptic structure and function.

Purpose of the Study:

  • To investigate the mRNA expression levels of the dendritic spine protein drebrin in the brains of Alzheimer's disease patients.
  • To explore the correlation between drebrin mRNA expression and key Alzheimer's disease biomarkers and clinical parameters.

Main Methods:

  • Post-mortem in situ hybridization was used to quantify drebrin mRNA in brain sections from AD patients and controls.
  • Alzheimer's disease diagnosis was confirmed by measuring levels of amyloid-beta (Abeta) and tau proteins.
  • Statistical analyses were performed to assess differences in drebrin mRNA and its correlations with other markers.

Main Results:

  • Significant decreases in drebrin mRNA were observed in the parietal cortex, temporal cortex, and hippocampus of AD patients compared to controls.
  • AD brains showed decreased drebrin protein and elevated levels of Abeta(40), Abeta(42), Abeta(42/40) ratio, total tau, and PHFtau.
  • Cortical drebrin mRNA levels correlated positively with soluble total tau but negatively with symptom duration and PHFtau.

Conclusions:

  • The down-regulation of drebrin mRNA expression is a significant finding in Alzheimer's disease.
  • Reduced drebrin mRNA is closely associated with the progression of Alzheimer's disease and tau pathology.
  • Drebrin mRNA levels may serve as a potential biomarker or therapeutic target in Alzheimer's disease research.

More Related Videos

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles04:22

Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles

Published on: May 20, 2024

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...